Loading
Jacobio Pharmaceuticals Group Co., Ltd. - B Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Wang-Gillam Andrea, was filed 19 Nov 2025.
Jacobio Pharmaceuticals Group Co., Ltd. - B: what insiders have been doing
Jacobio Pharmaceuticals Group Co., Ltd. - B is a Health Care company. Its directors and officers file their transactions with HKEX. Between 21 October 2025 and 21 October 2026, 1 insider published 1 filing.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase, made by 1 insider. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 senior executive.
Compared with its exchange (1,315 companies, median 4 filings), a count of 1 filing is below the norm. Looking back to 2021, when coverage begins, insiders filed 80 purchases and 28 sales.
The most recent open-market purchase was published on 19 November 2025, 336 days ago.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Insider Decl.
117
Thresholds
n/a
Buy Volume
€63M
80 ops. · all time
Sell Volume
€133M
28 ops. · all time
Who traded when
BuySaleHu Yunyan11 buys2 sales
Wang Xiaojie11 buys2 sales
Wang Yinxiang11 buys2 sales
Wang-Gillam Andrea1 buy
Since the insiders bought
- -46.0%Entry HK$11.34 · Close at T+365 HK$6.12
- -46.0%Entry HK$11.34 · Close at T+365 HK$6.12
- -46.0%Entry HK$11.34 · Close at T+365 HK$6.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,554 of 26,283 companies
60.3
score / 100
Value23
Quality98
FCF yld-5.2%
Earn yld-3.6%
EV/EBITDA·
ROE46%
Gross mgn99%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$5.23
Analyst consensus
2 analystsHK$9.32Target HK$9.87(+89%)HK$10.41
Income statement
RevenueHK$53.5M
Gross profitHK$52.9M99% margin
EBITDA-HK$110.2M-206% margin
Net income-HK$146M69.5% margin
Valuation
PER (trailing)7.1x
PER (forward)-209.0x
P/Book2.6x
Beta0.35
Balance sheet & cash
Market capHK$4.1B
Total debtHK$165.2M
Free Cash Flow-HK$212.7M
Debt / Equity12%
Profitability & ownership
ROE46.3%
ROA20.6%
% insiders35.7%
% institutions9.0%
Last declaration on 19 November 2025
Declarations117 total
5,000,000 sharesShareXHKGHKEX:DA20251119E00338
Canonical exit: 11 Feb 2026 (T+90)
1,000,000 shares@ HK$8.801.6% of flowShareXHKGHKEX:DA20250919E00457
1,000,000 shares@ HK$8.801.5% of flowShareXHKGHKEX:DA20250919E00456
209,100 shares@ HK$10.06180.4% of flowShareXHKGHKEX:DA20250905E00596
Canonical exit: 2 Dec 2025 (T+90)
209,100 shares@ HK$10.06180.4% of flowShareXHKGHKEX:DA20250905E00600
Canonical exit: 2 Dec 2025 (T+90)
192,300 shares@ HK$10.26720.4% of flowShareXHKGHKEX:DA20250905E00595
Canonical exit: 1 Dec 2025 (T+90)
192,300 shares@ HK$10.26720.3% of flowShareXHKGHKEX:DA20250905E00598
Canonical exit: 1 Dec 2025 (T+90)
600 shares@ HK$8.110.0% of flowShareXHKGHKEX:DA20250904E00456
Canonical exit: 30 Nov 2025 (T+90)
600 shares@ HK$8.110.0% of flowShareXHKGHKEX:DA20250904E00455
Canonical exit: 30 Nov 2025 (T+90)
2,100 shares@ HK$7.55430.0% of flowShareXHKGHKEX:DA20250731E00579
Canonical exit: 27 Oct 2025 (T+90)
2,100 shares@ HK$7.55430.0% of flowShareXHKGHKEX:DA20250731E00580
Canonical exit: 27 Oct 2025 (T+90)
4,200 shares@ HK$7.180.0% of flowShareXHKGHKEX:DA20250728E00416
Canonical exit: 23 Oct 2025 (T+90)
4,200 shares@ HK$7.180.0% of flowShareXHKGHKEX:DA20250728E00414
Canonical exit: 23 Oct 2025 (T+90)
54,600 shares@ HK$7.14110.1% of flowShareXHKGHKEX:DA20250728E00415
Canonical exit: 22 Oct 2025 (T+90)
54,600 shares@ HK$7.14110.1% of flowShareXHKGHKEX:DA20250728E00413
Canonical exit: 22 Oct 2025 (T+90)
221,100 shares@ HK$7.07590.3% of flowShareXHKGHKEX:DA20250724E00034
Canonical exit: 20 Oct 2025 (T+90)
221,100 shares@ HK$7.07590.3% of flowShareXHKGHKEX:DA20250724E00036
Canonical exit: 20 Oct 2025 (T+90)
25 of 117 declarations
About Jacobio Pharmaceuticals Group Co., Ltd. - B
Jacobio Pharmaceuticals Group Co., Ltd. is a biopharmaceutical company focused on the research and development of innovative drugs. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
